http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1097922-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-0033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
filingDate | 1999-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2005-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00b83aeb808dcee47f7f6b799e40dbca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fedf88b663bc51b1d1e30b524fd8b47 |
publicationDate | 2005-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1097922-B1 |
titleOfInvention | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
abstract | 5-Thia- omega -substituted phenyl-prostaglandin E derivatives represented by general formula (I) wherein each symbol is as defined in the specification. Because of being capable of bonding strongly to PEG2receptors (in particular, the subtype EP4), the compounds represented by general formula (I) are expected as useful in preventing and/or treating immunologic diseases, asthma, bone dysplasia, nerve cell death, lung failure, hepatopathy, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock, etc. Moreover, these compounds participate in sleep disorders and platelet aggregation and, therefore, are expected as useful in preventing/treating these diseases. <CHEM> |
priorityDate | 1998-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.